# Maintenance Tislelizumab + Capecitabine to Treat Metastatic Colorectal Cancer

Source: https://onco.cc/trials/nct05360277/  
OnCo record `nct05360277` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of tislelizumab and capecitabine in colorectal cancer, run by Yanhong Deng, now recruiting.

## Summary

Maintenance Tislelizumab + Capecitabine to Treat Metastatic Colorectal Cancer is a phase 2, randomised interventional study registered as NCT05360277 by Yanhong Deng, with a registry enrolment figure of 52 participants, started 2023-08-22 and due to reach its primary completion in 2025-02-28. Interventions recorded: Tislelizumab + Capecitabine; Best supportive care. Conditions listed: Metastatic Colorectal Cancer，NED. Primary outcome: Disease-free survival. Colorectal eligibility wording from the registry: "Surgery with integrated treatment for metastatic colorectal cancer (mCRC) and achieved a statute of no evidence of disease (NED), as determined by a multidisciplinary tumor board". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: CAMCO2
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT05360277
- Phase: 2
- Setting: Maintenance Tislelizumab Combined With Capecitabine to Treat Metastatic Colorectal Cancer With No Evidence of Disease
- Sponsor: Yanhong Deng
- Enrolled: 52

## Sources

- ClinicalTrials.gov NCT05360277: https://clinicaltrials.gov/study/NCT05360277

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/), [Tislelizumab](https://onco.cc/drugs/tislelizumab/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05360277.json